Key result
Heterologous COVID-19 vaccination linked to fulminant giant cell myocarditis requiring heart transplantation in one patient.
Case Report (n=1)
Clinicians should consider the possibility of giant cell myocarditis in patients presenting with rapidly deteriorating cardiac function after COVID-19 vaccination.
Answers are grounded in this paper and cite their sources.
Temporal association with fulminant giant cell myocarditis after heterologous vaccination; hypothesis-generating and leaves causality open.
A 48-year-old female patient underwent a heart transplantation for acute fulminant myocarditis, following heterologous vaccination with the ChAdOx1 nCoV-19 and Pfizer-BioNTech COVID-19. She had no history of severe acute respiratory syndrome coronavirus-2 infection. She did not exhibit clinical signs or have laboratory findings of concomitant infection before or after vaccination. Heart transplantation was performed because her heart failed to recover with venoarterial extracorporeal oxygenation support. Organ autopsy revealed giant cell myocarditis, possibly related to the vaccines. Clinicians may have to consider the possibility of the development of giant cell myocarditis, especially in patients with rapidly deteriorating cardiac function and myocarditis symptoms after COVID-19 vaccination.
No takes yet. Share an insight, caveat, or question.
Kang et al. (2022) conducted a case report in Fulminant giant cell myocarditis (n=1). Heterologous vaccination with ChAdOx1 nCoV-19 and Pfizer-BioNTech COVID-19 was evaluated. Heterologous vaccination with ChAdOx1 nCoV-19 and Pfizer-BioNTech COVID-19 was followed by fulminant giant cell myocarditis requiring heart transplantation in a 48-year-old female.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: